Wikidata

(Q61981525)

English

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

clinical trial

In more languages

Statements

sponsor
Novartis
0 references
country
Argentina
0 references
Austria
0 references
Belgium
0 references
Finland
0 references
Germany
0 references
Greece
0 references
Guatemala
0 references
Hungary
0 references
India
0 references
Israel
0 references
Italy
0 references
Latvia
0 references
Lithuania
0 references
Mexico
0 references
Norway
0 references
Peru
0 references
Poland
0 references
Romania
0 references
Slovakia
0 references
Venezuela
0 references
start time
February 2009
0 references
end time
March 2011
0 references
number of participants
1,988
0 references
research intervention
metformin
0 references
sitagliptin phosphate
0 references
vildagliptin
0 references
minimum age
18 year
0 references
maximum age
78 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q61981525&oldid=2095746106"